- Datum07.07.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Altan Cantürk
Moderator
Genfit S.A. Aktie
Verkaufen
Kaufen
Genfit S.A. Chart
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Genfit S.A. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (L&S)
0,67 %
Intraday
0,37 %
1 Woche
-11,41 %
1 Monat
-7,27 %
Seit Jahresbeginn
-12,45 %
1 Jahr
6,26 %
3 Jahre
-31,42 %
5 Jahre
-90,34 %
10 Jahre
Passender Service zu Genfit S.A.
Webinar zu Genfit S.A.
Kursinformationen (L&S)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)2,210-5,860
- Jahrestief / Hoch (€)2,210-4,192
- Schlusskurs (Vortag)
- Eröffnungskurs
Wichtigste Eigenschaften
Dividenden von Genfit S.A.
Keine Dividenden verfügbar
Termine von Genfit S.A.
Keine aktuellen Termine
Beschreibung
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
